A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)

A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)

This study will assess the safety and efficacy of ixekizumab (LY2439821), compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.


Study Type: Interventional  (Clinical Trial)
Actual Enrollment: 1346 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate to Severe Plaque Psoriasis With a Long-Term Extension Period
Actual Study Start Date: July 28, 2012
Actual Primary Completion Date: May 22, 2014
Estimated Study Completion Date: August 15, 2019

Arm:
- Placebo Comparator: Placebo
- Active Comparator: 50 mg etanercept
- Experimental: 80 mg ixekizumab Dosing Regimen 2
- Experimental: 80 mg ixekizumab Dosing Regimen 1